CD320

Across TCGA pan-cancer cohorts, CD320 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD320 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD320 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD320 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where CD320 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.271	0.949	.013	18	view →
LUAD	OS	Tertile	II,III,IV	0.273	0.715	.013	10	view →
HNSC	OS	Quartile	IV	0.415	0.891	.024	2	view →
LSCC	DFS	Tertile	III,IV	1.000	0.555	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD320–CCRCC (OS)

Open the CCRCC breakdown →